太原痔疮膏哪种好(太原大便滴血怎么回事) (今日更新中)

The Trump administration announced Wednesday plans to remove 12,000 US troops from Germany with some being returned to the United States, and others being relocated to other NATO allies.The Department of Defense says that 5,600 troops will be repositioned to other NATO nations, while 6,400 will be returned to the US.Defense Secretary Mark Esper told CNN that the move to relocate troops will cost in the billions.President Donald Trump said the move was made because Germany is taking “advantage” of the US.“They are there to protect Europe and there to protect Germany and Germany is supposed to pay for it,” Trump said on Wednesday. “And we don't want to be -- the United States has been taken advantage of for 25 years with trade and on the military. It's very simple, they are delinquent. Very simple. And there are other NATO countries also, there are 28 countries “While there have been concerns that removing troops from the region diminishes the US presence in Europe in keeping Russia in check, Esper said that the move will enhance its deterrence against Russia.“The repositioning of our forces in Europe constitutes a major strategic and positive shift, wholly in line with the NDS, and consistent with other adjustments the United States has made within NATO in previous times,” Esper said. “These changes achieve the core principles of enhancing U.S. and NATO deterrence of Russia; strengthening NATO; reassuring Allies; and, improving U.S. strategic flexibility and EUCOM operational flexibility.”The reduced presence in Germany cuts the number of troops stationed there by one-third. 1608

The toy run in December is usually one of the big ways Children's Hospital Colorado gets donated toys. But because of COVID-19, the supply of toys is down considerably. So the hospital reached out to some riders, and Sunday, they got a special delivery to help replenish that supply.Kids at Children's Hospital know when they hear those Harley engines roar, toys are on the way."Any motorcycles coming up to the hospital, the kids plaster themselves the windows. They love to see the bikes riding up," volunteer Bob Cuculich said."That's why we do it. It's things like this that make it all worthwhile," organizer Eddie Dane said.But it's not December when this toy run usually happens."Because of COVID this year, the hospital reached out to Rocky Mountain Harley Davidson, because we're a sponsor to the toy run and have been for years," Dane said.Dozens of bikers answered the last minute call to help."They're not reusing toys. So we are are going to replenish their supply and do the best we can to get them some more toys to last them until December," Dane said.They didn't know how many bikers would show. They just knew they needed to try to help the kids."There's a huge need," Cuculich said.But the roars were there, filling up the bins, and they hope more toys can be brought. Just no stuffed animals right now."Plush toys right now, they are just too hard to keep clean, and infection control just makes it a challenge to be able to give those to the kids," Cuculich added.The bikers hope this special delivery makes the kids happy and lasts until the main ride in December. Just a little Christmas in July.KMGH's Sean Towle first reported this story. 1671

The situation with Saudi Arabia right now is complicated: A journalist who most recently wrote for "The Washington Post" and who was a supporter of gender equality and freedom of personal expression in the country went missing in October 2018.Jamal Khashoggi was last seen Oct. 2 entering the Saudi Arabia consulate in Istanbul, Turkey, where he had gone to obtain papers for his planned marriage. He was reported missing when no CCTV recorded him leaving the consulate and there were rumors he had been killed and dismembered. 550

The US Food and Drug Administration expanded the list of drugs being recalled that contain valsartan. The drug is used as a component in a set of drugs used to treat heart failure and blood pressure.The FDA initially announced a valsartan recall in July after lab tests discovered that some drugs could have been tainted with a substance linked to higher risk of cancer. The drug had previously been recalled in 22 other countries. The expanded recall includes some drugs that contain valsartan and hydrochlorothisazide. Not all of the drugs containing valsartan were impacted.N-nitrosodimethylamine or NDMA, the impurity the lab tests found, is considered a possible carcinogen by the US Environmental Protection Agency. It is an organic chemical that has been used to make liquid rocket fuel, and can be unintentionally introduced through certain chemical reactions. It's a byproduct from the manufacturing of some pesticides and fish processing. 956

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

来源：资阳报